Valor pronóstico del nuevo sistema de etapificación internacional en mieloma múltiple: Comparación con el sistema de Durie-Salmon

• Guillermo Conté L ^[1] ; Gastón Figueroa M ^[1] ; Vivianne Lois V ^[3] ; María Elena Cabrera C ^[4] ; Alvaro León R ^[2] ; Hernán García L ^[5] ; Hernán Rojas R ^[6]
  1. [1] Universidad de Chile

     Universidad de Chile

     Santiago, Chile

     
  2. [2] Universidad Austral de Chile

     Universidad Austral de Chile

     Valdivia, Chile

     
  3. [3] Hospital Barros Luco T.
  4. [4] Hospital Salvador
  5. [5] Hospital San Borja A.
  6. [6] Hospital Sótero del Río

  Mostrar afiliaciones +
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 136, Nº. 1, 2008, págs. 7-12
• Idioma: español
• Títulos paralelos:
  • Prognostic value of the new international staging system in multiple myeloma: Comparison with Durie-Salmon staging system
• Enlaces
  • Texto completo
• Resumen

  • Background: Since 1975, the Durie-Salmon staging system (D&S) has been a widely accepted prognostic classification of multiple myeloma (MM) patients. Recently, the new International Staging System (ISS) was developed using only the values of albumin and betaZ-microglobulin. Aim: To compare survival of patients with MM treated in six medical centers in Chile according to the D&S system and the new ISS. Material and methods: Retrospective analysis of demographic information, clinical features and survival rate of patients treated between 1998 and 2002, and grouped according to both systems. Results: Information of 81 patients aged 38 to 90 years (43 women) was retrieved. According D&S system 11% were in stage I 12% in stage II and 73% in stage III According to ISS, 34% were in stage I 35% in stage II and 31% in stage III Median of survival of all patients was 32 months. Both staging systems had a prognostic value. However, median survival for the three stages of the ISS system was significantly different (67, 29 and 14 months in stages III and III, respectively, p =0.02). Patients in advanced stages II and III of the ISS, had a higher frequency of anemia, hypercalcemia, renal failure and hypoalbuminemia. In stages II and III of ISS the presence of renal failure was associated with a non significantly different lower survival. Conclusions: The ISS is a simple and effective grouping method for patients with MM, that predicts survival. The presence of renal insufficiency might identify a subgroup of patients included in stages II and III of ISS with a higher mortality (Rev Méd Chile 2008; 136: 7-12)